{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:18:15Z","timestamp":1783973895494,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36035-x","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:16:25Z","timestamp":1770218185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Higher lymph node burden predicts greater chemotherapy benefit in resected pancreatic ductal adenocarcinoma: evidence from 22,045 patients"],"prefix":"10.1038","volume":"16","author":[{"given":"Jun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1441-9841","authenticated-orcid":false,"given":"Ling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"36035_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop, T. F. et al. Pancreatic cancer. Lancet 405, 1182\u20131202 (2025).","journal-title":"Lancet"},{"key":"36035_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics. CA. Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA. Cancer J. Clin."},{"key":"36035_CR3","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395\u20132406 (2018).","journal-title":"N. Engl. J. Med."},{"key":"36035_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos, J. P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet Lond. Engl. 389, 1011\u20131024 (2017).","journal-title":"Lancet Lond. Engl."},{"key":"36035_CR5","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/bjs\/znad146","volume":"110","author":"L Maggino","year":"2023","unstructured":"Maggino, L. et al. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Br. J. Surg. 110, 973\u2013982 (2023).","journal-title":"Br. J. Surg."},{"key":"36035_CR6","unstructured":"AJCC Cancer Staging Manual. (Springer, New York, NY, 2017)."},{"key":"36035_CR7","first-page":"1240","volume":"43","author":"DH Palmer","year":"2025","unstructured":"Palmer, D. H. et al. Pancreatic adenocarcinoma: long-term outcomes of adjuvant therapy in the ESPAC4 phase III trial. J. Clin. Oncol. 43, 1240\u20131253 (2025).","journal-title":"J. Clin. Oncol."},{"key":"36035_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.hpb.2019.07.008","volume":"22","author":"DK DePeralta","year":"2020","unstructured":"DePeralta, D. K. et al. Completion of adjuvant therapy in patients with resected pancreatic cancer. HPB 22, 241\u2013248 (2020).","journal-title":"HPB"},{"key":"36035_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2013.50.7657","volume":"32","author":"JW Valle","year":"2014","unstructured":"Valle, J. W. et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J. Clin. Oncol. 32, 504\u2013512 (2014).","journal-title":"J. Clin. Oncol."},{"key":"36035_CR10","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1245\/s10434-024-14951-4","volume":"31","author":"S Paiella","year":"2024","unstructured":"Paiella, S. et al. Adjuvant therapy after upfront resection of resectable pancreatic cancer: patterns of omission and use-a prospective real-life study. Ann. Surg. Oncol. 31, 2892\u20132901 (2024).","journal-title":"Ann. Surg. Oncol."},{"key":"36035_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.hpb.2019.06.019","volume":"22","author":"TM Mackay","year":"2020","unstructured":"Mackay, T. M. et al. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. HPB 22, 233\u2013240 (2020).","journal-title":"HPB"},{"key":"36035_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fonc.2020.00041","volume":"10","author":"QP Janssen","year":"2020","unstructured":"Janssen, Q. P., O\u2019Reilly, E. M., van Eijck, C. H. J. & Groot Koerkamp, B. Neoadjuvant treatment in patients with resectable and borderline resectable pancreatic cancer. Front. Oncol. 10, 41 (2020).","journal-title":"Front. Oncol."},{"key":"36035_CR13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1089\/thy.2023.0561","volume":"34","author":"S Liu","year":"2024","unstructured":"Liu, S. et al. Vitamin E Intake and Prevalence Rates of Thyroid Dysfunction and Autoimmune Thyroiditis: A Cross-Sectional Analysis of NHANES Data. Thyroid 34, 753\u2013763 (2024).","journal-title":"Thyroid"},{"key":"36035_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/annonc\/mdv500","volume":"27","author":"KS Tewari","year":"2016","unstructured":"Tewari, K. S., Java, J. J., Eskander, R. N., Monk, B. J. & Burger, R. A. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG oncology\/gynecologic oncology group study. Ann. Oncol. 27, 114\u2013121 (2016).","journal-title":"Ann. Oncol."},{"key":"36035_CR15","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/oxfordjournals.aje.a008670","volume":"143","author":"FJ Nieto","year":"1996","unstructured":"Nieto, F. J. & Coresh, J. Adjusting survival curves for confounders: A review and a new method. Am. J. Epidemiol. 143, 1059\u20131068 (1996).","journal-title":"Am. J. Epidemiol."},{"key":"36035_CR16","doi-asserted-by":"publisher","first-page":"8041","DOI":"10.1038\/s41467-023-43064-x","volume":"14","author":"C Ding","year":"2023","unstructured":"Ding, C. et al. Binge-pattern alcohol consumption and genetic risk as determinants of alcohol-related liver disease. Nat. Commun. 14, 8041 (2023).","journal-title":"Nat. Commun."},{"key":"36035_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/ije\/dyr218","volume":"41","author":"MJ Knol","year":"2012","unstructured":"Knol, M. J. & VanderWeele, T. J. Recommendations for presenting analyses of effect modification and interaction. Int. J. Epidemiol. 41, 514\u2013520 (2012).","journal-title":"Int. J. Epidemiol."},{"key":"36035_CR18","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1097\/SLA.0000000000003558","volume":"274","author":"L Huang","year":"2021","unstructured":"Huang, L. et al. Significance of examined lymph node number in accurate staging and long-term survival in resected stage I-II pancreatic cancer-more is better? A large international population-based cohort study. Ann. Surg. 274, e554\u2013e563 (2021).","journal-title":"Ann. Surg."},{"key":"36035_CR19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy, T. et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 8, 1571\u20131578 (2022).","journal-title":"JAMA Oncol."},{"key":"36035_CR20","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1007\/s00423-022-02686-3","volume":"407","author":"R Hamura","year":"2022","unstructured":"Hamura, R. et al. The effectiveness of adjuvant chemotherapy for stage I pancreatic cancer based on the UICC 8th edition. Langenbecks Arch. Surg. 407, 3437\u20133446 (2022).","journal-title":"Langenbecks Arch. Surg."},{"key":"36035_CR21","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/ijc.34044","volume":"151","author":"M Guenther","year":"2022","unstructured":"Guenther, M. et al. The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. Int. J. Cancer 151, 914\u2013919 (2022).","journal-title":"Int. J. Cancer"},{"key":"36035_CR22","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.surg.2024.07.047","volume":"176","author":"Y Zou","year":"2024","unstructured":"Zou, Y. et al. Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk. Surgery 176, 1466\u20131474 (2024).","journal-title":"Surgery"},{"key":"36035_CR23","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1007\/s10147-025-02742-0","volume":"30","author":"K Kobayashi","year":"2025","unstructured":"Kobayashi, K. et al. Prognostic impact of dose reduced S-1 adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: a retrospective multicenter study. Int. J. Clin. Oncol. 30, 1218\u20131228 (2025).","journal-title":"Int. J. Clin. Oncol."},{"key":"36035_CR24","doi-asserted-by":"publisher","first-page":"e0263250","DOI":"10.1371\/journal.pone.0263250","volume":"17","author":"J Muhammadzai","year":"2022","unstructured":"Muhammadzai, J. et al. Early discontinuation of adjuvant chemotherapy in patients with early-stage pancreatic cancer correlates with inferior survival: A multicenter population-based cohort study. PLoS ONE 17, e0263250 (2022).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36035-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36035-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36035-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T11:15:01Z","timestamp":1771586101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36035-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36035"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36035-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Since the SEER database is publicly available, this study was exempt from review by the Ethics Committee of the authors\u2019 hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was waived due to the use of de-identified data from the SEER public database.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}],"article-number":"7227"}}